A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer’s disease

Rosie Freer,Pietro Sormanni,Giulia Vecchi,Prajwal Ciryam,Christopher M. Dobson,Michele Vendruscolo

DOI: https://doi.org/10.1126/sciadv.1600947

IF: 13.6

2016-08-05

Science Advances

Abstract:A tissue vulnerability map based on Aβ and tau homeostasis in healthy brains predicts the staging of Alzheimer’s disease.

multidisciplinary sciences

What problem does this paper attempt to address?

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

Keenan A Walker,Jingsha Chen,Liu Shi,Yunju Yang,Myriam Fornage,Linda Zhou,Pascal Schlosser,Aditya Surapaneni,Morgan E Grams,Michael R Duggan,Zhongsheng Peng,Gabriela T Gomez,Adrienne Tin,Ron C Hoogeveen,Kevin J Sullivan,Peter Ganz,Joni V Lindbohm,Mika Kivimaki,Alejo J Nevado-Holgado,Noel Buckley,Rebecca F Gottesman,Thomas H Mosley,Eric Boerwinkle,Christie M Ballantyne,Josef Coresh

DOI: https://doi.org/10.1126/scitranslmed.adf5681

2023-07-19

Abstract:A diverse set of biological processes have been implicated in the pathophysiology of Alzheimer's disease (AD) and related dementias. However, there is limited understanding of the peripheral biological mechanisms relevant in the earliest phases of the disease. Here, we used a large-scale proteomics platform to examine the association of 4877 plasma proteins with 25-year dementia risk in 10,981 middle-aged adults. We found 32 dementia-associated plasma proteins that were involved in proteostasis, immunity, synaptic function, and extracellular matrix organization. We then replicated the association between 15 of these proteins and clinically relevant neurocognitive outcomes in two independent cohorts. We demonstrated that 12 of these 32 dementia-associated proteins were associated with cerebrospinal fluid (CSF) biomarkers of AD, neurodegeneration, or neuroinflammation. We found that eight of these candidate protein markers were abnormally expressed in human postmortem brain tissue from patients with AD, although some of the proteins that were most strongly associated with dementia risk, such as GDF15, were not detected in these brain tissue samples. Using network analyses, we found a protein signature for dementia risk that was characterized by dysregulation of specific immune and proteostasis/autophagy pathways in adults in midlife ~20 years before dementia onset, as well as abnormal coagulation and complement signaling ~10 years before dementia onset. Bidirectional two-sample Mendelian randomization genetically validated nine of our candidate proteins as markers of AD in midlife and inferred causality of SERPINA3 in AD pathogenesis. Last, we prioritized a set of candidate markers for AD and dementia risk prediction in midlife.
A Map of Transcriptomic Signatures of Different Brain Areas in Alzheimer's Disease

Riccardo Rocco Ferrari,Valentina Fantini,Maria Garofalo,Rosalinda Di Gerlando,Francesca Dragoni,Bartolo Rizzo,Erica Spina,Michele Rossi,Chiara Calatozzolo,Xhulja Profka,Mauro Ceroni,Antonio Guaita,Annalisa Davin,Stella Gagliardi,Tino Emanuele Poloni

DOI: https://doi.org/10.3390/ijms252011117

IF: 5.6

2024-10-16

International Journal of Molecular Sciences

Abstract:Alzheimer's disease (AD) is a neurodegenerative disorder that progressively involves brain regions with an often-predictable pattern. Damage to the brain appears to spread and worsen with time, but the molecular mechanisms underlying the region-specific distribution of AD pathology at different stages of the disease are still under-investigated. In this study, a whole-transcriptome analysis was carried out on brain samples from the hippocampus (HI), temporal and parietal cortices (TC and PC, respectively), cingulate cortex (CG), and substantia nigra (SN) of six subjects with a definite AD diagnosis and three healthy age-matched controls in duplicate. The transcriptomic results showed a greater number of differentially expressed genes (DEGs) in the TC (1571) and CG (1210) and a smaller number of DEGs in the HI (206), PC (109), and SN (60). Furthermore, the GSEA showed a difference between the group of brain areas affected early (HI and TC) and the group of areas that were subsequently involved (PC, CG, and SN). Notably, in the HI and TC, there was a significant downregulation of shared DEGs primarily involved in synaptic transmission, while in the PC, CG, and SN, there was a significant downregulation of genes primarily involved in protein folding and trafficking. The course of AD could follow a definite time- and severity-related pattern that arises from protein misfolding, as observed in the PC, CG, and SN, and leads to synaptic impairment, as observed in the HI and TC. Therefore, a map of the molecular and biological processes involved in AD pathogenesis may be traced. This could aid in the discovery of novel biological targets in order to develop effective and well-timed therapeutic approaches.

biochemistry & molecular biology,chemistry, multidisciplinary
Cytokine expression patterns predict suppression of vulnerable neural circuits in a mouse model of Alzheimer's disease

Dennis C Chan,ChaeMin Kim,Rachel Y Kang,Madison K Kuhn,Lynne M Beidler,Nanyin Zhang,Elizabeth A Proctor

DOI: https://doi.org/10.1101/2024.03.17.585383

2024-03-17

bioRxiv

Abstract:Alzheimer's disease is a neurodegenerative disorder characterized by progressive amyloid plaque accumulation, tau tangle formation, neuroimmune dysregulation, synapse an neuron loss, and changes in neural circuit activation that lead to cognitive decline and dementia. Early molecular and cellular disease-instigating events occur 20 or more years prior to presentation of symptoms, making them difficult to study, and for many years amyloid-β, the aggregating peptide seeding amyloid plaques, was thought to be the toxic factor responsible for cognitive deficit. However, strategies targeting amyloid-β aggregation and deposition have largely failed to produce safe and effective therapies, and amyloid plaque levels poorly correlate with cognitive outcomes. However, a role still exists for amyloid-β in the variation in an individual's immune response to early, soluble forms of aggregates, and the downstream consequences of this immune response for aberrant cellular behaviors and creation of a detrimental tissue environment that harms neuron health and causes changes in neural circuit activation. Here, we perform functional magnetic resonance imaging of awake, unanesthetized Alzheimer's disease mice to map changes in functional connectivity over the course of disease progression, in comparison to wild-type littermates. In these same individual animals, we spatiotemporally profile the immune milieu by measuring cytokines, chemokines, and growth factors across various brain regions and over the course of disease progression from pre-pathology through established cognitive deficit. We identify specific signatures of immune activation predicting hyperactivity followed by suppression of intra- and then inter-regional functional connectivity in multiple disease-relevant brain regions, following the pattern of spread of amyloid pathology.
Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer's Disease Brain

Sonia Podvin,Zhenze Jiang,Ben Boyarko,Leigh-Ana Rossitto,Anthony O'Donoghue,Robert A Rissman,Vivian Hook

DOI: https://doi.org/10.1021/acschemneuro.2c00222

2022-07-06

Abstract:Synaptic dysfunction and loss occur in Alzheimer's disease (AD) brains, which results in cognitive deficits and brain neurodegeneration. Neuropeptides comprise the major group of synaptic neurotransmitters in the nervous system. This study evaluated neuropeptide signatures that are hypothesized to differ in human AD brain compared to age-matched controls, achieved by global neuropeptidomics analysis of human brain cortex synaptosomes. Neuropeptidomics demonstrated distinct profiles of neuropeptides in AD compared to controls consisting of neuropeptides derived from chromogranin A (CHGA) and granins, VGF (nerve growth factor inducible), cholecystokinin, and others. The differential neuropeptide signatures indicated differences in proteolytic processing of their proneuropeptides. Analysis of cleavage sites showed that dibasic residues at the N-termini and C-termini of neuropeptides were the main sites for proneuropeptide processing, and data also showed that the AD group displayed differences in preferred residues adjacent to the cleavage sites. Notably, tau peptide signatures differed in the AD compared to age-matched control human brain cortex synaptosomes. Unique tau peptides were derived from the tau protein through proteolysis using similar and differential cleavage sites in the AD brain cortex compared to the control. Protease profiles differed in the AD compared to control, indicated by proteomics data. Overall, these results demonstrate that dysregulation of neuropeptides and tau peptides occurs in AD brain cortex synaptosomes compared to age-matched controls, involving differential cleavage site properties for proteolytic processing of precursor proteins. These dynamic changes in neuropeptides and tau peptide signatures may be associated with the severe cognitive deficits of AD.
Single-cell expression predicts neuron-specific protein homeostasis networks

Sebastian Pechmann

DOI: https://doi.org/10.1098/rsob.230386

2024-01-24

Open Biology

Abstract:The protein homeostasis network keeps proteins in their correct shapes and avoids unwanted aggregation. In turn, the accumulation of aberrantly misfolded proteins has been directly associated with the onset of ageing-associated neurodegenerative diseases such as Alzheimer's and Parkinson's. However, a detailed and rational understanding of how protein homeostasis is achieved in health, and how it can be targeted for therapeutic intervention in diseases remains missing. Here, large-scale single-cell expression data from the Allen Brain Map are analysed to investigate the transcription regulation of the core protein homeostasis network across the human brain. Remarkably, distinct expression profiles suggest specialized protein homeostasis networks with systematic adaptations in excitatory neurons, inhibitory neurons and non-neuronal cells. Moreover, several chaperones and Ubiquitin ligases are found transcriptionally coregulated with genes important for synapse formation and maintenance, thus linking protein homeostasis to the regulation of neuronal function. Finally, evolutionary analyses highlight the conservation of an elevated interaction density in the chaperone network, suggesting that one of the most exciting aspects of chaperone action may yet be discovered in their collective action at the systems level. More generally, our work highlights the power of computational analyses for breaking down complexity and gaining complementary insights into fundamental biological problems.

biochemistry & molecular biology
Cytokine expression patterns predict suppression of vulnerable neural circuits in a mouse model of Alzheimer’s disease

Dennis C. Chan,ChaeMin Kim,Rachel Y. Kang,Madison K. Kuhn,Lynne M. Beidler,Nanyin Zhang,Elizabeth A. Proctor

DOI: https://doi.org/10.1101/2024.03.17.585383

2024-03-18

Abstract:Alzheimer’s disease is a neurodegenerative disorder characterized by progressive amyloid plaque accumulation, tau tangle formation, neuroimmune dysregulation, synapse an neuron loss, and changes in neural circuit activation that lead to cognitive decline and dementia. Early molecular and cellular disease-instigating events occur 20 or more years prior to presentation of symptoms, making them difficult to study, and for many years amyloid-β, the aggregating peptide seeding amyloid plaques, was thought to be the toxic factor responsible for cognitive deficit. However, strategies targeting amyloid-β aggregation and deposition have largely failed to produce safe and effective therapies, and amyloid plaque levels poorly correlate with cognitive outcomes. However, a role still exists for amyloid-β in the variation in an individual’s immune response to early, soluble forms of aggregates, and the downstream consequences of this immune response for aberrant cellular behaviors and creation of a detrimental tissue environment that harms neuron health and causes changes in neural circuit activation. Here, we perform functional magnetic resonance imaging of awake, unanesthetized Alzheimer’s disease mice to map changes in functional connectivity over the course of disease progression, in comparison to wild-type littermates. In these same individual animals, we spatiotemporally profile the immune milieu by measuring cytokines, chemokines, and growth factors across various brain regions and over the course of disease progression from pre-pathology through established cognitive deficit. We identify specific signatures of immune activation predicting hyperactivity followed by suppression of intra- and then inter-regional functional connectivity in multiple disease-relevant brain regions, following the pattern of spread of amyloid pathology.

Neuroscience
Brain network fingerprints of Alzheimer's disease risk factors in mouse models with humanized APOE alleles

Steven Winter,Ali Mahzarnia,Robert J Anderson,Zay Yar Han,Jessica Tremblay,Jacques A Stout,Hae Sol Moon,Daniel Marcellino,David B Dunson,Alexandra Badea

DOI: https://doi.org/10.1016/j.mri.2024.110251

Abstract:Alzheimer's disease (AD) presents complex challenges due to its multifactorial nature, poorly understood etiology, and late detection. The mechanisms through which genetic and modifiable risk factors influence disease susceptibility are under intense investigation, with APOE being the major genetic risk factor for late onset AD. Yet the impact of unique risk factors on brain networks is difficult to disentangle, and their interactions remain unclear. To model multiple risk factors, including APOE genotype, age, sex, diet, and immunity we used a cross sectional design, leveraging mice expressing human APOE and NOS2 genes, conferring a reduced immune response compared to mouse Nos2. We used network topological and GraphClass analyses of brain connectomes derived from accelerated diffusion-weighted MRI to assess the global and local impact of risk factors, in the absence of AD pathology. Aging and a high-fat diet impacted extensive networks comprising AD-vulnerable regions, including the temporal association cortex, amygdala, and the periaqueductal gray, involved in stress responses. Sex impacted networks including sexually dimorphic regions (thalamus, insula, hypothalamus) and key memory-processing areas (fimbria, septum). APOE genotypes modulated connectivity in memory, sensory, and motor regions, while diet and immunity both impacted the insula and hypothalamus. Notably, these risk factors converged on a circuit comprising 63 of 54,946 total connections (0.11% of the connectome), highlighting shared vulnerability amongst multiple AD risk factors in regions essential for sensory integration, emotional regulation, decision making, motor coordination, memory, homeostasis, and interoception. APOE genotype specific immune signatures support the design of interventions tailored to risk profiles. Sparse Canonical Correlation Analysis (CCA) including spatial memory as a risk factor resulted in a network comprising 80 edges, showing significant overlap with risk-associated networks from GraphClass. The largest overlaps were observed with networks impacted by diet (47 edges), immunity (39 edges), APOE3 vs 4 (26 edges), sex (23 edges), and age (19 edges), the resulting networks supporting the use of sensory cues in spatial memory retrieval. These network-based biomarkers hold translational value for distinguishing high-risk versus low-risk participants at preclinical AD stages, suggest circuits as potential therapeutic targets, and advance our understanding of network fingerprints associated with AD risk.
Interrogation of the human cortical peptidome uncovers cell-type specific signatures of cognitive resilience against Alzheimer's disease

G. R. Morgan,B. C. Carlyle

DOI: https://doi.org/10.1038/s41598-024-57104-z

IF: 4.6

2024-03-28

Scientific Reports

Abstract:Alzheimer's disease (AD) is characterised by age-related cognitive decline. Brain accumulation of amyloid-β plaques and tau tangles is required for a neuropathological AD diagnosis, yet up to one-third of AD-pathology positive community-dwelling elderly adults experience no symptoms of cognitive decline during life. Conversely, some exhibit chronic cognitive impairment in absence of measurable neuropathology, prompting interest into cognitive resilience—retained cognition despite significant neuropathology—and cognitive frailty—impaired cognition despite low neuropathology. Synapse loss is widespread within the AD-dementia, but not AD-resilient, brain. Recent evidence points towards critical roles for synaptic proteins, such as neurosecretory VGF, in cognitive resilience. However, VGF and related proteins often signal as peptide derivatives. Here, nontryptic peptidomic mass spectrometry was performed on 102 post-mortem cortical samples from individuals across cognitive and neuropathological spectra. Neuropeptide signalling proteoforms derived from VGF, somatostatin (SST) and protachykinin-1 (TAC1) showed higher abundance in AD-resilient than AD-dementia brain, whereas signalling proteoforms of cholecystokinin (CCK) and chromogranin (CHG) A/B and multiple cytoskeletal molecules were enriched in frail vs control brain. Integrating our data with publicly available single nuclear RNA sequencing (snRNA-seq) showed enrichment of cognition-related genes in defined cell-types with established links to cognitive resilience, including SST interneurons and excitatory intratelencephalic cells.

multidisciplinary sciences
Dynamics of waste proteins in brain tissue: Numerical insights into Alzheimer's risk factors

Lily Watkins,Saikat Mukherjee,Jeffrey Tithof

DOI: https://doi.org/10.1103/PhysRevE.110.034401

Abstract:Over the past few decades, research has indicated that the buildup of waste proteins, like amyloid-β (Aβ), in the brain's interstitial spaces is linked to neurodegenerative diseases like Alzheimer's, but the details of how such proteins are removed from the brain are not well understood. We have developed a numerical model to investigate the aggregation and clearance mechanisms of Aβ in the interstitial spaces of the brain. The model describes the volume-averaged transport of Aβ in a segment of the brain interstitium modeled as a porous medium, oriented between the perivascular space (fluid-filled channel surrounding a blood vessel) of a penetrating arteriole and that of a venule. Our numerical approach solves N coupled advection-diffusion-aggregation equations that model the production, aggregation, fragmentation, and clearance of N species of Aβ. We simulate N=50 species to investigate the oligomer-size dependence of clearance and aggregation. We introduce a timescale plot that helps predict Aβ buildup for different neurological conditions. We show that a sudden increase in monomer concentration, as occurs in conditions like traumatic brain injury, leads to significant plaque formation, which can qualitatively be predicted using the timescale plot. Our results also indicate that impaired protein clearance (as occurs with aging) and fragmentation are both mechanisms that sustain large intermediate oligomer concentrations. Our results provide novel insight into several known risk factors for Alzheimer's disease and cognitive decline, and we introduce a unique framing of Aβ dynamics as a competition between different timescales associated with production rates, aggregation rates, and clearance conditions.
A brain signature highly predictive of future progression to Alzheimer's dementia

Christian Dansereau,Angela Tam,AmanPreet Badhwar,Sebastian Urchs,Pierre Orban,Pedro Rosa-Neto,Pierre Bellec

DOI: https://doi.org/10.48550/arXiv.1712.08058

2017-12-21

Quantitative Methods

Abstract:Early prognosis of Alzheimer's dementia is hard. Mild cognitive impairment (MCI) typically precedes Alzheimer's dementia, yet only a fraction of MCI individuals will progress to dementia, even when screened using biomarkers. We propose here to identify a subset of individuals who share a common brain signature highly predictive of oncoming dementia. This signature was composed of brain atrophy and functional dysconnectivity and discovered using a machine learning model in patients suffering from dementia. The model recognized the same brain signature in MCI individuals, 90% of which progressed to dementia within three years. This result is a marked improvement on the state-of-the-art in prognostic precision, while the brain signature still identified 47% of all MCI progressors. We thus discovered a sizable MCI subpopulation which represents an excellent recruitment target for clinical trials at the prodromal stage of Alzheimer's disease.
Transcriptome Signatures for Cognitive Resilience Among Individuals with Pathologically Confirmed Alzheimer Disease

Donghe Li,Xudong Han,Lindsay A Farrer,Gyungah R Jun

DOI: https://doi.org/10.1101/2024.11.12.24317218

2024-11-13

Abstract:INTRODUCTION: Limited success to date in development of drugs that target hallmark Alzheimer disease (AD) proteins as a means to slow AD-related cognitive decline has sparked interest in approaches focused on cognitive resilience. We sought to identify transcriptome signatures among brain donors with neuropathologically confirmed AD that distinguish those with cognitive impairment from those that were cognitively intact. METHODS: We compared gene expression patterns in brain tissue from donors in four cohorts who were cognitively and pathologically normal (controls), met clinical and pathological criteria for AD (SymAD), or were cognitively normal prior to death despite pathological evidence of AD (cognitively resilient or AsymAD). Differentially expressed genes (DEGs) at the transcriptome-wide significance (TWS) level (P<10-6) in the total sample and nominally significant (P<0.05) in at least two datasets were further evaluated in analyses testing association of gene expression with co-calibrated and harmonized cognitive domain scores and AD-related neuropathological traits. RESULTS: We identified 52 TWS DEGs, including 14 that surpassed a significance threshold of P<5x10-8. The three most significant DEGs, ADAMTS2 (Log2 fold change [Log2FC]=0.46, P=2.94x10-14), S100A4 (Log2FC=0.61, P=3.98x10-11) and NRIP2 (Log2FC=0.32, P=9.52x10-11) were up-regulated in SymAD compared to AsymAD brains. ADAMTS2 and SLC6A9 were also significantly and nominally differentially expressed between AsymAD cases and controls (FDR P=0.45 and FDR P=0.57, respectively). Significant associations (P<0.0038) were identified for executive function with expression of ADAMTS2 (P=4.15x10-8) and ARSG (P=1.09x10-3), and for memory with PRELP (P=3.92x10-5) and EMP3 (P=7.75x10-4), and for language with SLC38A2 (P=6.76x10-5) and SLC6A9 (P=2.13 x10-3). Expression of ARSG and FHIP1B were associated with measures of Tau pathology (AT8: P=1.5x10-3, and pTau181: P=3.64x10-3, respectively), and SLC6A9 expression was associated with multiple pTau isoforms including pTau181 (P=1.5x10-3) and pTau396 (P=2.05x10-3). PRELP expression was associated with synaptic density (PSD.95: P=6.18x10-6). DEGs were significantly enriched in pathways involving E2F targets, cholesterol homeostasis, and oxidative phosphorylation. CONCLUSION: We identified multiple DEGs that differentiate neuropathologically confirmed AD cases with and without cognitive impairment prior to death. Expression of several of these genes was also associated with measures of cognitive performance and AD-related neuropathological traits, thus providing important insights into cognitive resilience mechanisms and strategies for delaying clinical symptoms of AD.
Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Alexa Pichet Binette,Chris Gaiteri,Malin Wennström,Atul Kumar,Ines Hristovska,Nicola Spotorno,Gemma Salvadó,Olof Strandberg,Hansruedi Mathys,Li-Huei Tsai,Sebastian Palmqvist,Niklas Mattsson-Carlgren,Shorena Janelidze,Erik Stomrud,Jacob W Vogel,Oskar Hansson

DOI: https://doi.org/10.1038/s41593-024-01737-w

2024-08-26

Abstract:Proteomics can shed light on the dynamic and multifaceted alterations in neurodegenerative disorders like Alzheimer disease (AD). Combining radioligands measuring β-amyloid (Aβ) plaques and tau tangles with cerebrospinal fluid proteomics, we uncover molecular events mirroring different stages of AD pathology in living humans. We found 127 differentially abundant proteins (DAPs) across the AD spectrum. The strongest Aβ-related proteins were mainly expressed in glial cells and included SMOC1 and ITGAM. A dozen proteins linked to ATP metabolism and preferentially expressed in neurons were independently associated with tau tangle load and tau accumulation. Only 20% of the DAPs were also altered in other neurodegenerative diseases, underscoring AD's distinct proteome. Two co-expression modules related, respectively, to protein metabolism and microglial immune response encompassed most DAPs, with opposing, staggered trajectories along the AD continuum. We unveil protein signatures associated with Aβ and tau proteinopathy in vivo, offering insights into complex neural responses and potential biomarkers and therapeutics targeting different disease stages.
Biological mechanisms of resilience to tau pathology in Alzheimer's disease

Anna L Svenningsson,Diana I Bocancea,Erik Stomrud,Anita van Loenhoud,Frederik Barkhof,Niklas Mattsson-Carlgren,Sebastian Palmqvist,Oskar Hansson,Rik Ossenkoppele

DOI: https://doi.org/10.1186/s13195-024-01591-9

2024-10-12

Abstract:Background: In Alzheimer's disease (AD), the associations between tau pathology and brain atrophy and cognitive decline are well established, but imperfect. We investigate whether cerebrospinal fluid (CSF) biomarkers of biological processes (vascular, synaptic, and axonal integrity, neuroinflammation, neurotrophic factors) explain the disconnection between tau pathology and brain atrophy (brain resilience), and tau pathology and cognitive decline (cognitive resilience). Methods: We included 428 amyloid positive participants (134 cognitively unimpaired (CU), 128 with mild cognitive impairment (MCI), 166 with AD dementia) from the BioFINDER-2 study. At baseline, participants underwent tau positron emission tomography (tau-PET), magnetic resonance imaging (MRI), cognitive testing, and lumbar puncture. Longitudinal data were available for MRI (mean (standard deviation) follow-up 26.4 (10.7) months) and cognition (25.2 (11.4) months). We analysed 18 pre-selected CSF proteins, reflecting vascular, synaptic, and axonal integrity, neuroinflammation, and neurotrophic factors. Stratifying by cognitive status, we performed linear mixed-effects models with cortical thickness (brain resilience) and global cognition (cognitive resilience) as dependent variables to assess whether the CSF biomarkers interacted with tau-PET levels in its effect on cortical atrophy and cognitive decline. Results: Regarding brain resilience, interaction effects were observed in AD dementia, with vascular integrity biomarkers (VEGF-A (βinteraction = -0.009, pFDR = 0.047) and VEGF-B (βinteraction = -0.010, pFDR = 0.037)) negatively moderating the association between tau-PET signal and atrophy. In MCI, higher NfL levels were associated with more longitudinal cortical atrophy (β = -0.109, pFDR = 0.033) and lower baseline cortical thickness (β = -0.708, pFDR = 0.033) controlling for tau-PET signal. Cognitive resilience analyses in CU revealed interactions with tau-PET signal for inflammatory (GFAP, IL-15; βinteraction -0.073--0.069, pFDR 0.001-0.045), vascular (VEGF-A, VEGF-D, PGF; βinteraction -0.099--0.063, pFDR < 0.001-0.046), synaptic (14-3-3ζ/δ; βinteraction = -0.092, pFDR = 0.041), axonal (NfL; βinteraction = -0.079, pFDR < 0.001), and neurotrophic (NGF; βinteraction = 0.091, pFDR < 0.001) biomarkers. In MCI higher NfL levels (βmain = -0.690, pFDR = 0.025) were associated with faster cognitive decline independent of tau-PET signal. Conclusions: Biomarkers of co-existing pathological processes, in particular vascular pathology and axonal degeneration, interact with levels of tau pathology on its association with the downstream effects of AD pathology (i.e. brain atrophy and cognitive decline). This indicates that vascular pathology and axonal degeneration could impact brain and cognitive resilience.
Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimers disease

Hamilton Se-Hwee Oh,Deniz Yagmur Urey,Linda Karlsson,Zeyu Zhu,Yuanyuan Shen,Amelia Farinas,Jigyasha Timsina,Ian H Guldner,Nader Morshed,Chengran Yang,Daniel Western,Muhammad Ali,Yann Le Guen,Alexandra Trelle,Sanna-Kaisa Herukka,Tuomas Rauramaa,Mikko Hiltunen,Anssi Lipponen,Antti J Luikku,Kathleen L Poston,Elizabeth Mormino,Anthony D Wagner,Edward N Wilson,Divya Channappa,Ville Leinonen,Beth Stevens,Alexander J Ehrenberg,Henrik Zetterberg,David A Bennett,Nico Franzmeier,Oskar Hansson,Carlos Cruchaga,Tony Wyss-Coray

DOI: https://doi.org/10.1101/2024.07.22.604680

2024-07-23

Abstract:Rates of cognitive decline in Alzheimers disease (AD) are extremely heterogeneous, with ages of symptom onset ranging from age 40 to 100 years and conversion from mild cognitive impairment to AD dementia taking 2 to 20 years. Development of biomarkers for amyloid-beta (AB) and tau protein aggregates, the hallmark pathologies of AD, have improved patient monitoring/stratification and drug development, but they still only explain 20 to 40% of the variance in cognitive impairment (CI) in AD. To discover additional molecular drivers and biomarkers of AD dementia, we perform cerebrospinal fluid (CSF) proteomics on 3,416 individuals from six deeply phenotyped prospective AD case-control cohorts. We identify synapse proteins as the strongest correlates of CI, independent of AB; and tau. Using machine learning we derive the CSF YWHAG:NPTX2 synapse protein ratio, a robust correlate of CI, which explains 27% of the variance in CI beyond CSF PTau181:AB42, 10% beyond tau PET, and 50% beyond CSF NfL in AB positive individuals. We find YWHAG:NPTX2 also increases with normal aging as early as age 20 and increases at a faster rate in APOE4 carriers and autosomal dominant AD mutation carriers. Most notably, YWHAG:NPTX2 positive individuals (top 25th percentile) are 15 times (HR=15.4 [10.6 to 22.2]) more likely to experience cognitive decline over 15 years compared to YWHAG:NPTX2 negative individuals (bottom 25th percentile), and this rises to 19 times (HR=18.9 [10.83 to 32.9]) with additional stratification by AB and phosphorylated tau status. Lastly, we perform plasma proteomics on 4,245 individuals to develop a plasma-based signature of CI which partly recapitulates CSF YWHAG:NPTX2. Overall, our findings underscore CSF YWHAG:NPTX2 and the corresponding plasma signature as robust prognostic biomarkers for AD onset and progression beyond gold-standard biomarkers of AB, tau, and neurodegeneration and implicate synapse dysfunction as a core driver of AD dementia.

Neuroscience
In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer's disease

Lazaro M. Sanchez-Rodriguez,Ahmed F. Khan,Quadri Adewale,Gleb Bezgin,Joseph Therriault,Jaime Fernandez-Arias,Stijn Servaes,Nesrine Rahmouni,Cécile Tissot,Jenna Stevenson,Hongxiu Jiang,Xiaoqian Chai,Felix Carbonell,Pedro Rosa-Neto,Yasser Iturria-Medina

DOI: https://doi.org/10.3389/fnagi.2024.1383163

IF: 4.8

2024-06-20

Frontiers in Aging Neuroscience

Abstract:The molecular mechanisms underlying neuronal dysfunction in Alzheimer's disease (AD) remain uncharacterized. Here, we identify genes, molecular pathways and cellular components associated with whole-brain dysregulation caused by amyloid-beta (Aβ) and tau deposits in the living human brain. We obtained in-vivo resting-state functional MRI (rs-fMRI), Aβ- and tau-PET for 47 cognitively unimpaired and 16 AD participants from the Translational Biomarkers in Aging and Dementia cohort. Adverse neuronal activity impacts by Aβ and tau were quantified with personalized dynamical models by fitting pathology-mediated computational signals to the participant's real rs-fMRIs. Then, we detected robust brain-wide associations between the spatial profiles of Aβ-tau impacts and gene expression in the neurotypical transcriptome (Allen Human Brain Atlas). Within the obtained distinctive signature of in-vivo neuronal dysfunction, several genes have prominent roles in microglial activation and in interactions with Aβ and tau. Moreover, cellular vulnerability estimations revealed strong association of microglial expression patterns with Aβ and tau's synergistic impact on neuronal activity ( q < 0.001). These results further support the central role of the immune system and neuroinflammatory pathways in AD pathogenesis. Neuronal dysregulation by AD pathologies also associated with neurotypical synaptic and developmental processes. In addition, we identified drug candidates from the vast LINCS library to halt or reduce the observed Aβ-tau effects on neuronal activity. Top-ranked pharmacological interventions target inflammatory, cancer and cardiovascular pathways, including specific medications undergoing clinical evaluation in AD. Our findings, based on the examination of molecular-pathological-functional interactions in humans, may accelerate the process of bringing effective therapies into clinical practice.

neurosciences,geriatrics & gerontology,gerontology
Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease

Yona Levites,Eric B Dammer,Yong Ran,Wangchen Tsering,Duc Duong,Measho Abreha,Joshna Gadhavi,Kiara Lolo,Jorge Trejo-Lopez,Jennifer Phillips,Andrea Iturbe,Aya Erquizi,Brenda D Moore,Danny Ryu,Aditya Natu,Kristy Dillon,Jose Torrellas,Corey Moran,Thomas Ladd,Farhana Afroz,Tariful Islam,Jaishree Jagirdar,Cory C Funk,Max Robinson,Srikant Rangaraju,David R Borchelt,Nilüfer Ertekin-Taner,Jeffrey W Kelly,Frank L Heppner,Erik C B Johnson,Karen McFarland,Allan I Levey,Stefan Prokop,Nicholas T Seyfried,Todd E Golde

DOI: https://doi.org/10.1016/j.xcrm.2024.101669

2024-08-20

Abstract:Alzheimer's disease (AD) is a complex neurodegenerative disorder that develops over decades. AD brain proteomics reveals vast alterations in protein levels and numerous altered biologic pathways. Here, we compare AD brain proteome and network changes with the brain proteomes of amyloid β (Aβ)-depositing mice to identify conserved and divergent protein networks with the conserved networks identifying an Aβ amyloid responsome. Proteins in the most conserved network (M42) accumulate in plaques, cerebrovascular amyloid (CAA), and/or dystrophic neuronal processes, and overexpression of two M42 proteins, midkine (Mdk) and pleiotrophin (PTN), increases the accumulation of Aβ in plaques and CAA. M42 proteins bind amyloid fibrils in vitro, and MDK and PTN co-accumulate with cardiac transthyretin amyloid. M42 proteins appear intimately linked to amyloid deposition and can regulate amyloid deposition, suggesting that they are pathology modifiers and thus putative therapeutic targets. We posit that amyloid-scaffolded accumulation of numerous M42+ proteins is a central mechanism mediating downstream pathophysiology in AD.
Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

Yona Levites,Eric B Dammer,Yong Ran,Wangchen Tsering,Duc Duong,Measho Abreha,Joshna Gadhavi,Kiara Lolo,Jorge Trejo-Lopez,Jennifer L Phillips,Andrea Iturbe,Aya Erqiuzi,Brenda Dawn Moore,Danny Ryu,Aditya Natu,Kristy D Dillon,Jose Torrellas,Corey Moran,Thomas B Ladd,Kazi Farhana Afroz,Tariful Islam,Jaishree Jagirdar,Cory C Funk,Max Robinson,David R Borchelt,Nilufer Ertekin-Taner,Jeffrey W Kelly,Frank L Heppner,Erik Cb Johnson,Karen McFarland,Allan L Levey,Stefan Prokop,Nicholas T Seyfried,Todd E Golde

DOI: https://doi.org/10.1101/2023.11.29.568318

2023-12-07

bioRxiv

Abstract:We report a highly significant correlation in brain proteome changes between Alzheimers disease (AD) and CRND8 APP695NL/F transgenic mice. However, integrating protein changes observed in the CRND8 mice with co-expression networks derived from human AD, reveals both conserved and divergent module changes. For the most highly conserved module (M42, matrisome) we find many proteins accumulate in plaques, cerebrovascular amyloid (CAA), dystrophic processes, or a combination thereof. Overexpression of two M42 proteins, midkine (Mdk) and pleiotrophin (PTN), in CRND8 mice brains leads to increased accumulation of A β ; in plaques and in CAA; further, recombinant MDK and PTN enhance A β ; aggregation into amyloid. Multiple M42 proteins, annotated as heparan sulfate binding proteins, bind to fibrillar A β 42 and a non-human amyloid fibril in vitro. Supporting this binding data, MDK and PTN co-accumulate with transthyretin (TTR) amyloid in the heart and islet amyloid polypeptide (IAPP) amyloid in the pancreas. Our findings establish several critical insights. Proteomic changes in modules observed in human AD brains define an A β ; amyloid responsome that is well conserved from mouse model to human. Further, distinct amyloid structures may serve as scaffolds, facilitating the co-accumulation of proteins with signaling functions. We hypothesize that this co-accumulation may contribute to downstream pathological sequalae. Overall, this contextualized understanding of proteomic changes and their interplay with amyloid deposition provides valuable insights into the complexity of AD pathogenesis and potential biomarkers and therapeutic targets.
Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer's pathology

Prateek Kumar,Annie M Goettemoeller,Claudia Espinosa-Garcia,Brendan R Tobin,Ali Tfaily,Ruth S Nelson,Aditya Natu,Eric B Dammer,Juliet V Santiago,Sneha Malepati,Lihong Cheng,Hailian Xiao,Duc D Duong,Nicholas T Seyfried,Levi B Wood,Matthew J M Rowan,Srikant Rangaraju

DOI: https://doi.org/10.1038/s41467-024-47028-7

2024-04-01

Abstract:Dysfunction in fast-spiking parvalbumin interneurons (PV-INs) may represent an early pathophysiological perturbation in Alzheimer's Disease (AD). Defining early proteomic alterations in PV-INs can provide key biological and translationally-relevant insights. We used cell-type-specific in-vivo biotinylation of proteins (CIBOP) coupled with mass spectrometry to obtain native-state PV-IN proteomes. PV-IN proteomic signatures include high metabolic and translational activity, with over-representation of AD-risk and cognitive resilience-related proteins. In bulk proteomes, PV-IN proteins were associated with cognitive decline in humans, and with progressive neuropathology in humans and the 5xFAD mouse model of Aβ pathology. PV-IN CIBOP in early stages of Aβ pathology revealed signatures of increased mitochondria and metabolism, synaptic and cytoskeletal disruption and decreased mTOR signaling, not apparent in whole-brain proteomes. Furthermore, we demonstrated pre-synaptic defects in PV-to-excitatory neurotransmission, validating our proteomic findings. Overall, in this study we present native-state proteomes of PV-INs, revealing molecular insights into their unique roles in cognitive resiliency and AD pathogenesis.
Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer’s disease in the 3xTg-AD mouse model

Alfonso Grimaldi,Carlo Brighi,Giovanna Peruzzi,Davide Ragozzino,Valentina Bonanni,Cristina Limatola,Giancarlo Ruocco,Silvia Di Angelantonio

DOI: https://doi.org/10.1038/s41419-018-0740-5

2018-06-01

Cell Death and Disease

Abstract:Alzheimer's disease (AD) is the most common cause of dementia in the elderly. In the pathogenesis of AD a pivotal role is played by two neurotoxic proteins that aggregate and accumulate in the central nervous system: amyloid beta and hyper-phosphorylated tau. Accumulation of extracellular amyloid beta plaques and intracellular hyper-phosphorylated tau tangles, and consequent neuronal loss begins 10–15 years before any cognitive impairment. In addition to cognitive and behavioral deficits, sensorial abnormalities have been described in AD patients and in some AD transgenic mouse models. Retina can be considered a simple model of the brain, as some pathological changes and therapeutic strategies from the brain may be observed or applicable to the retina. Here we propose new retinal biomarkers that could anticipate the AD diagnosis and help the beginning and the follow-up of possible future treatments. We analyzed retinal tissue of triple-transgenic AD mouse model (3xTg-AD) for the presence of pathological hallmarks during disease progression. We found the presence of amyloid beta plaques, tau tangles, neurodegeneration, and astrogliosis in the retinal ganglion cell layer of 3xTg-AD mice, already at pre-symptomatic stage. Moreover, retinal microglia in pre-symptomatic mice showed a ramified, anti-inflammatory phenotype which, during disease progression, switches to a pro-inflammatory, less ramified one, becoming neurotoxic. We hypothesize retina as a window through which monitor AD-related neurodegeneration process.

cell biology
Analysis of Brain Protein Stability Changes in a Mouse Model of Alzheimer's Disease

Yun Tang,Hye-Jin Park,Shengyu Li,Michael C Fitzgerald

DOI: https://doi.org/10.1021/acs.jproteome.4c00406

2024-10-04

Abstract:The stability of proteins from rates of oxidation (SPROX), thermal proteome profiling (TPP), and limited proteolysis (LiP) techniques were used to profile the stability of ∼2500 proteins in hippocampus tissue cell lysates from 2- and 8-months-old wild-type (C57BL/6J; n = 7) and transgenic (5XFAD; n = 7) mice with five Alzheimer's disease (AD)-linked mutations. Approximately 200-500 protein hits with AD-related stability changes were detected by each technique at each age point. The hit overlap from technique to technique was low, and all of the techniques generated protein hits that were more numerous and largely different from those identified in protein expression level analyses, which were also performed here. The hit proteins identified by each technique were enriched in a number of the same pathways and biological processes, many with known connections to AD. The protein stability hits included 25 high-value conformation biomarkers with AD-related stability changes detected using at least 2 techniques at both age points. Also discovered were subunit- and age-specific AD-related stability changes in the proteasome, which had reduced function at both age points. The different folding stability profiles of the proteasome at the two age points are consistent with a different mechanism for proteasome dysfunction at the early and late stages of AD.

A protein homeostasis signature in healthy brains recapitulates tissue vulnerability to Alzheimer’s disease

Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life

A Map of Transcriptomic Signatures of Different Brain Areas in Alzheimer's Disease

Cytokine expression patterns predict suppression of vulnerable neural circuits in a mouse model of Alzheimer's disease

Dysregulation of Neuropeptide and Tau Peptide Signatures in Human Alzheimer's Disease Brain

Single-cell expression predicts neuron-specific protein homeostasis networks

Cytokine expression patterns predict suppression of vulnerable neural circuits in a mouse model of Alzheimer’s disease

Brain network fingerprints of Alzheimer's disease risk factors in mouse models with humanized APOE alleles

Interrogation of the human cortical peptidome uncovers cell-type specific signatures of cognitive resilience against Alzheimer's disease

Dynamics of waste proteins in brain tissue: Numerical insights into Alzheimer's risk factors

A brain signature highly predictive of future progression to Alzheimer's dementia

Transcriptome Signatures for Cognitive Resilience Among Individuals with Pathologically Confirmed Alzheimer Disease

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies

Biological mechanisms of resilience to tau pathology in Alzheimer's disease

Synapse protein signatures in cerebrospinal fluid and plasma predict cognitive maintenance versus decline in Alzheimers disease

In-vivo neuronal dysfunction by Aβ and tau overlaps with brain-wide inflammatory mechanisms in Alzheimer's disease

Integrative proteomics identifies a conserved Aβ amyloid responsome, novel plaque proteins, and pathology modifiers in Alzheimer's disease

Aβ Amyloid Scaffolds the Accumulation of Matrisome and Additional Proteins in Alzheimer's Disease

Native-state proteomics of Parvalbumin interneurons identifies unique molecular signatures and vulnerabilities to early Alzheimer's pathology

Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer’s disease in the 3xTg-AD mouse model

Analysis of Brain Protein Stability Changes in a Mouse Model of Alzheimer's Disease